TOP TEN perturbations for 38816_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38816_at
Selected probe(set): 202289_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38816_at (202289_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

Langerhans cell histiocytosis study 2 (unifocal) / normal epidermal Langerhans cell sample

Relative Expression (log2-ratio):-4.5443325
Number of Samples:8 / 10
Experimental Langerhans cell histiocytosis study 2 (unifocal)
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with unifocal, single system disease (bone lesion).
Control normal epidermal Langerhans cell sample
Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue.

Langerhans cell histiocytosis study 2 (multifocal) / normal epidermal Langerhans cell sample

Relative Expression (log2-ratio):-4.4461956
Number of Samples:2 / 10
Experimental Langerhans cell histiocytosis study 2 (multifocal)
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal (bone, skin lesions) disease.
Control normal epidermal Langerhans cell sample
Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue.

Langerhans cell histiocytosis study 2 (multisystem) / normal epidermal Langerhans cell sample

Relative Expression (log2-ratio):-4.173321
Number of Samples:2 / 10
Experimental Langerhans cell histiocytosis study 2 (multisystem)
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal, multisystem (disseminated) disease. Both patients received chemotherapy. Sites of LCH lesions: subj.ID:1 (skin, lungs, multiple skull, mastoid, gingiva), subj.ID:13 (mandible, skull, vertebrae, recurrent orbit, liver, spleen, pituitary gland).
Control normal epidermal Langerhans cell sample
Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue.

expO skin cancer study 1 (squamous cell carcinoma, NOS; metastatic) / expO skin cancer study 1 (malignant melanoma, NOS; metastatic)

Relative Expression (log2-ratio):3.9015322
Number of Samples:2 / 9
Experimental expO skin cancer study 1 (squamous cell carcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary squamous cell carcinoma (NOS) of the skin.
Control expO skin cancer study 1 (malignant melanoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary malignant melanoma (NOS) of the skin.

melanoma study 34 (metastatic) / melanoma study 34 (in situ)

Relative Expression (log2-ratio):-3.849103
Number of Samples:40 / 2
Experimental melanoma study 34 (metastatic)
Metastatic tumor tissue sample obtained from the patients with metastatic malignant melanoma of the skin. Metastatic samples composed of 22 macroscopic lymph node metastases, 16 subcutaneous metastases and 2 solid organ metastases (adrenal and brain).
Control melanoma study 34 (in situ)
Tumor tissue from the skin of patients with melanoma in situ.

melanoma study 34 (metastatic) / normal skin tissue

Relative Expression (log2-ratio):-3.7735815
Number of Samples:40 / 4
Experimental melanoma study 34 (metastatic)
Metastatic tumor tissue sample obtained from the patients with metastatic malignant melanoma of the skin. Metastatic samples composed of 22 macroscopic lymph node metastases, 16 subcutaneous metastases and 2 solid organ metastases (adrenal and brain).
Control normal skin tissue
Normal skin tissue.

expO ovary cancer study 1 (mucinous adenocarcinoma; primary) / expO ovary cancer study 1 (carcinoma, undifferentiated type, NOS; primary)

Relative Expression (log2-ratio):3.6583672
Number of Samples:6 / 2
Experimental expO ovary cancer study 1 (mucinous adenocarcinoma; primary)
Primary tumor tissue samples obtained from the ovary of patients with mucinous adenocarcinoma.
Control expO ovary cancer study 1 (carcinoma, undifferentiated type, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with carcinoma, undifferentiated type (NOS).

precursor-B-ALL study 2 (E2A-PBX1) / precursor-B-ALL study 2 (hyperdiploid)

Relative Expression (log2-ratio):3.5769396
Number of Samples:2 / 27
Experimental precursor-B-ALL study 2 (E2A-PBX1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control precursor-B-ALL study 2 (hyperdiploid)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Dutch Childhood Oncology Group (DCOG).

precursor-B-ALL study 2 (E2A-PBX1) / T-ALL study 2

Relative Expression (log2-ratio):3.5491428
Number of Samples:2 / 13
Experimental precursor-B-ALL study 2 (E2A-PBX1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control T-ALL study 2
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Dutch Childhood Oncology Group (DCOG).

R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-3.4529123
Number of Samples:2 / 4
Experimental R547 study 1 (24h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 ╬╝mol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.